1.74
+0.01(+0.58%)
Currency In USD
| Previous Close | 1.73 |
| Open | 1.72 |
| Day High | 1.78 |
| Day Low | 1.69 |
| 52-Week High | 6.77 |
| 52-Week Low | 1.15 |
| Volume | 2.23M |
| Average Volume | 4.4M |
| Market Cap | 275.73M |
| PE | -3.7 |
| EPS | -0.47 |
| Moving Average 50 Days | 1.84 |
| Moving Average 200 Days | 2.66 |
| Change | 0.01 |
If you invested $1000 in Humacyte, Inc. (HUMA) since IPO date, it would be worth $179.94 as of October 01, 2025 at a share price of $1.74. Whereas If you bought $1000 worth of Humacyte, Inc. (HUMA) shares 3 years ago, it would be worth $542.06 as of October 01, 2025 at a share price of $1.74.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus
GlobeNewswire Inc.
Sep 29, 2025 12:00 PM GMT
– Patent covers esophagus produced using Humacyte’s proprietary bioengineered regenerative tissue platform, designed for implant in patients with damaged esophagus – – Patent provides coverage into 2041 for the composition of novel bioengineered esop
Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)
GlobeNewswire Inc.
Sep 18, 2025 11:00 AM GMT
- Results were published in JACC: Basic to Translational Science - - Publication evaluated coronary tissue engineered vessel (CTEV) as a conduit for CABG in a nonhuman primate model - - All implanted CTEVs remained patent through six months, demonstr
Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™
GlobeNewswire Inc.
Sep 15, 2025 11:00 AM GMT
- Results were published in the Journal of Vascular Surgery - - Publication described treatment of patients with Symvess who had hospital-acquired iatrogenic injuries or complications of vascular surgical procedures - - Patients treated with Symvess